Novo Nordisk $NVO Poised for Potential 51% Surge After Wave...
Novo Nordisk stands at a pivotal juncture with its GLP-1 drugs, Ozempic and Wegovy, driving substantial growth in the rapidly expanding obesity market. Despite fierce competition from Eli Lilly and...